Zomedica Announces Launch of eACTH Assay for Truforma(R) Platform
Zomedica Corp. (NYSE American: ZOM) has launched its new eACTH assay for the TRUFORMA In-Clinic Biosensor Testing Platform. This assay enables veterinarians to quickly differentiate between pituitary and adrenal dependent Cushing's syndrome in dogs, addressing a major gap in diagnostic accessibility. The assay is available for shipment as of April 4, 2022, directly from Zomedica, promising to enhance diagnostics and improve practice health for veterinarians.
- Launch of eACTH assay enhances diagnostic capabilities for veterinarians.
- Enables point-of-care testing, improving accessibility and reliability of results.
- None.
ANN ARBOR, MI / ACCESSWIRE / April 4, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay - endogenous ACTH (eACTH) - for the TRUFORMA In-Clinic Biosensor Testing Platform.
Larry Heaton, Zomedica's Chief Executive Officer, commented, "The proprietary TRUFORMA eACTH assay will bring a valuable diagnostic tool for veterinarians into their clinic for the first time. This new assay for the TRUFORMA instrument is an example of Zomedica's ongoing focus to meet the needs of clinical veterinarians in ways that promote both patient and practice health."
The TRUFORMA eACTH assay will offer veterinarians the ability to quickly differentiate between pituitary dependent (PDH) and adrenal dependent (ADH) Cushing's syndrome to inform management for the disease. Measurement of eACTH is the most effective way to distinguish between pituitary and adrenal dependent Cushing's disease in dogs. However, this test is not commonly used due to the instability of the eACTH molecule which makes sending samples to a reference lab difficult and unreliable. The TRUFORMA platform allows for measurement of eACTH at the point of care for the first time, making this valuable diagnostic assay readily accessible to practitioners.
"Endogenous ACTH measurement is one of the most useful and straight-forward diagnostics for differentiation between pituitary-dependent and adrenal-dependent hyperadrenocorticism, says Patty Lathan VMD, MS, DACVIM. Unfortunately, stringent sample handling requirements for shipping to an outside laboratory also make it one of the most under-used diagnostics."
The TRUFORMA eACTH assay is available for shipping April 4, 2022, directly from Zomedica.
For more information on Zomedica please visit www.zomedica.com.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- Twitter: https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Reader Advisory
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company's products, the Company's ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve
the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
PCG Advisory Group
Kirin Smith, President
ksmith@pcgadvisory.com
+1.646.823.8656
SOURCE: Zomedica Corp.
View source version on accesswire.com:
https://www.accesswire.com/695755/Zomedica-Announces-Launch-of-eACTH-Assay-for-TruformaR-Platform
FAQ
What is the eACTH assay launched by Zomedica?
When was the eACTH assay launched?
What platform does the eACTH assay utilize?
How does the eACTH assay benefit veterinarians?
